Consultation outcome

Proposal to make Maloff Protect 250mg/100mg film-coated tablets available from Pharmacies

This consultation has concluded

Download the full outcome

Detail of outcome

The Medicines and Healthcare products Regulatory Agency (MHRA) has agreed to reclassify Maloff Protect from a prescription only medicine (POM) to a Pharmacy (P) medicine in the UK for the prevention of malaria in adults weighing more than 40kg travelling to areas where malaria is widespread

See the public assessment report for more information.

Feedback received

Royal College of Physicians response

Royal Pharmaceutical Society response

Dispensing Doctor's Association Limited response

Lond Sutton Medical Centre response

Wyvern Pharmacy response

WR Evans Healthcare Limited response

Detail of feedback received

A total of 8 responses were received, of which 4 were in favour, 3 were not in favour and one was unsure. Two of the responses were confidential.

See all the responses to this consultation.

Original consultation


We are considering making Maloff Protect anti-malaria tablets available to buy from pharmacies. We always want to involve the public and healthcare professionals in decision that affect them. We want to know what you think about this change.

This consultation ran from

Consultation description

We want to know what you think

  • Maloff Protect will be used in the prevention of malaria in adults travelling to areas where malaria is prevalent.
  • Maloff, which contains the same active ingredients as Maloff Protect is only at the moment available on prescription.
  • We propose to make Maloff Protect available in pharmacies.
  • The MHRA considers that this product can be available as a Pharmacy medicine.
  • We want to know what you think about this change.

Please tell us your views using the form at the end of the attached pdf.

The deadline for comments is 6 April 2017.


Published 16 March 2017
Last updated 3 July 2017 + show all updates
  2. First published.